FY2024 EPS Estimates for Femasys Lowered by HC Wainwright

Femasys Inc. (NASDAQ:FEMY) – Investment analysts at HC Wainwright decreased their FY2024 earnings per share estimates for Femasys in a research report issued on Tuesday, February 11th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.87) for the year, down from their prior estimate of ($0.84). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Femasys’ Q4 2024 earnings at ($0.25) EPS, FY2025 earnings at ($0.68) EPS, FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.32) EPS and FY2028 earnings at ($0.19) EPS.

Separately, Chardan Capital lowered their price target on Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Femasys Stock Up 4.5 %

Shares of FEMY opened at $1.38 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. Femasys has a one year low of $0.86 and a one year high of $2.40. The stock’s fifty day moving average is $1.14 and its 200-day moving average is $1.12.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The business had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in Femasys by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 216,164 shares of the company’s stock worth $238,000 after acquiring an additional 9,681 shares during the period. Virtu Financial LLC acquired a new position in Femasys during the fourth quarter worth about $25,000. XTX Topco Ltd grew its holdings in Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after acquiring an additional 18,004 shares during the period. Finally, Aljian Capital Management LLC acquired a new position in Femasys during the third quarter worth about $27,000. 65.27% of the stock is owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.